Skip to content

Cannabis research published in 2024

98 studies whose primary subject is cannabis were published in 2024, down from 166 in 2023. Newest first. Back to the cannabis overview

Studies

Sustained Remission in Cannabis-Induced Psychosis treated as Schizophrenia

Journal of Psychiatrists Association of Nepal December 31, 2024 Puja Neupane, Shailendra Raj Adhikari, Ansuda Poudel et al.

Cannabis-induced psychosis and schizophrenia can present with similar symptoms making difficulties in diagnosis and treatment. We, herein, present a case of 34-year-old male with history of long term use of cannabis. He initially presented with symptoms suggestive of schizophrenia and was treated with antipsychotics. Patient would go in remission but whenever he is exposed to cannabis, would...

Psychosis associated with cannabis withdrawal: systematic review and case series

The British Journal of Psychiatry December 3, 2024 Edward Chesney, Thomas J. Reilly, Fraser Scott et al.

Background Abrupt cessation of heavy cannabis use can cause a withdrawal syndrome characterised by irritability, anxiety, insomnia, reduced appetite and restlessness. Recent reports have also described people in whom cannabis withdrawal immediately preceded the acute onset of psychosis. Aims To identify cases of psychosis associated with cannabis withdrawal. Method We completed a systematic...

Perspectives on cannabis risks and harm reduction among youth in Early Psychosis Intervention programs: a qualitative study

Mental Health and Social Inclusion December 2, 2024 Amar Ghelani

Purpose The Canadian government legalized cannabis in 2018 and funded harm reduction campaigns to educate youth about the risks. Cannabis can contribute to psychosis in vulnerable populations, and consumption is common among youth in Early Psychosis Intervention (EPI) programs. The purpose of this study is to understand the views of youth in EPI programs on the risks related to cannabis and...

Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Female Mice.

Cannabis and Cannabinoid Research December 1, 2024 Alexa Torrens, Alex Mabou Tagne, Adren Tran et al.

Introduction: Animal studies suggest that adolescent exposure to Δ9-tetrahydrocannabinol (Δ9-THC), the intoxicating constituent of cannabis, causes lasting functional alterations in brain and other organs. Those studies often neglect the impact that age- and sex-dependent differences in the distribution and metabolism of the drug might exert on its pharmacological effects. Here, we provide a...

Prenatal THC exposure drives sex-specific alterations in spatial memory and hippocampal excitatory/inhibitory balance in adolescent rats.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie December 1, 2024 Valentina Castelli, Gianluca Lavanco, Giuseppe Tringali et al.

The interaction between the main psychotropic ingredient of Cannabis, Δ⁹- tetrahydrocannabinol (THC), with the endogenous cannabinoid system (ECS) is a critical and underrated issue that deserves utmost attention. The ECS, indeed, contributes to the formation and regulation of excitatory and inhibitory (E/I) neuronal networks that in the hippocampus underly spatial memory. This study explored...

DOI: 10.1016/j.biopha.2024.117699 (opens in new tab) Full text (opens in new tab) Excitatory/inhibitory balance Hippocampus Prenatal THC Exposure Sex-related vulnerability +1

Potential Risks from Cannabis- Infused Beverages: A Critical Review

Cannabis November 26, 2024 Anna Marie Froude, Nikki Pangborn, Phillip Britz-McKibbin et al.

Although Canada legalized cannabis beverages in 2019, most available research on acute cannabis intoxication derives from dried flower and edible products. The distinct bioavailability and pharmacokinetic properties of phytocannabinoids ingested from beverages, however, contribute to significantly different acute and long-term effects that need to be better understood to ensure consumer safety....

Study links adolescent cannabis use with psychosis

Alcoholism & Drug Abuse Weekly November 8, 2024 Alison Knopf

A cohort study of 11,868 adolescents found that those who used cannabis at any point reported a greater number of psychosis symptoms, and more distress from those symptoms, compared to teens who never used cannabis. This study, “Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation,” published last week in JAMA Psychiatry, sought to answer the question of whether the...

Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation.

JAMA Psychiatry November 6, 2024 PhD K.JustonOsborne, PhD DeannaM.Barch, PhD JoshuaJ.Jackson et al.

Importance Adolescent cannabis use has been consistently posited to contribute to the onset and progression of psychosis. However, alternative causal models may account for observed associations between cannabis use and psychosis risk, including shared vulnerability for both cannabis use and psychosis or efforts to self-medicate distress from psychosis spectrum symptomology. Objective To test 3...

Exploring the substitution of cannabis for alcohol and other drugs among a large convenience sample of people who use cannabis.

Harm Reduction Journal November 5, 2024 Chris Wilkins, Jose Romeo, Marta Rychert et al. 8 citations

The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as where cannabis is used to reduce the negative side-effects, addiction potential, and social stigma of other drugs. There is currently mixed evidence with recent reviews suggesting cannabis co-use patterns may vary by age and ethnicity. Yet few studies have had large enough samples...

Cannabis use and cognitive biases in people with first-episode psychosis and their siblings

Psychological Medicine November 1, 2024 L. Roldán, Teresa Sánchez‐Gutiérrez, I. Fernández-Arias et al.

Background Cannabis use and familial vulnerability to psychosis have been associated with social cognition deficits. This study examined the potential relationship between cannabis use and cognitive biases underlying social cognition and functioning in patients with first episode psychosis (FEP), their siblings, and controls. Methods We analyzed a sample of 543 participants with FEP, 203...

Which comes first, first episode psychosis or cannabis use?

The Brown University Child and Adolescent Behavior Letter November 1, 2024 Alison Knopf

The typical conundrum with cannabis use by adolescents and first episode psychosis — which came first? — was displaced by Steven Batki, M.D., in a plenary session at the Cape Cod Symposium on Addictive Disorders (CCSAD) in September. Bakti, who is a professor of psychiatry at the University of California San Francisco Weill Institute for Neurosciences, presented his conclusions allowing the...

Regular cannabis use modulates gamma activity in brain regions serving motor control.

Journal of Psychopharmacology November 1, 2024 Lauren K Webert, Mikki Schantell, Jason A John et al.

People who regularly use cannabis exhibit altered brain dynamics during cognitive control tasks, though the impact of regular cannabis use on the neural dynamics serving motor control remains less understood. We sought to investigate how regular cannabis use modulates the neural dynamics serving motor control. Thirty-four people who regularly use cannabis (cannabis+) and 33 nonusers (cannabis-)...

DOI: 10.1177/02698811241268876 (opens in new tab) Full text (opens in new tab) Cannabis use Gamma Magnetoencephalography Motor control +1

New insight in psychotic cannabis withdrawal: case series and brief overview

Rivista di psichiatria November 1, 2024 Valerio Ricci, Domenico de Berardis, Giovanni Martinotti et al. 2 citations

BACKGROUND: Cannabis is the most used recreational drug worldwide. Its use can increase the risk of developing psychotic disorders and exacerbate their course. However, little is known about the relationship between psychosis and withdrawal and the literature is still scarce. CASE PRESENTATION: In this study, based on an analysis of 4 patients referred to our mental health department and...

Event-level associations among THC, CBD, social context, and subjective effects during Cannabis use episodes.

Journal of Psychopharmacology November 1, 2024 Yi-Chun Chang, Renee E Magnan, Michael J Cleveland et al. 2 citations

Limited research considers the quantity and potency of cannabis products along with social context on the subjective effects of real-world cannabis use. This study examined the subjective effects of acute use as a function of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) doses and social context during cannabis use episodes. Ninety-six participants (43.75% male, Mage = 35.73) reporting...

Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ9-Tetrahydrocannabinol Without Improving Its Analgesic Properties.

Clinical Pharmacology & Therapeutics November 1, 2024 Andriy A Gorbenko, Jules A A C Heuberger, Linda E. Klumpers et al. 17 citations

Cannabidiol (CBD), the main non-intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial investigated the hypothesis that CBD counteracts the adverse effects of THC and thereby potentially improves the tolerability of cannabis as an analgesic. A...

Reviewing the Risk of Ketene Formation in Dabbing and Vaping Tetrahydrocannabinol-O-Acetate.

Cannabis and Cannabinoid Research October 1, 2024 Carlton Cb Bone, Charles Klein, Kaelas Munger et al. 6 citations

Introduction: In the wake of continued consumer demand despite increasing regulatory scrutiny, there is a need to develop systematic methods for identifying the harm profile of new psychoactive substances derived from hemp. Tetrahydrocannabinol-O (THC-O)-acetate, colloquially known as THCO, is the acetate ester of the principal psychoactive compound in cannabis. The heating of THCO can create...

DOI: 10.1089/can.2023.0094 (opens in new tab) Full text (opens in new tab) Thco Cannabinoid acetate Dabbing and vaping Ketene

Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study.

Psychopharmacology October 1, 2024 Ardavan Mohammad Aghaei, Lia Urban Spillane, Brian Pittman et al. 9 citations

Recent reports have shown increased cannabis use among women, leading to growing concerns about cannabis use disorder (CUD). While there is preclinical evidence suggesting biological sex influences cannabinoid effects, human research remains scant. We investigated sex differences in the acute response to oral tetrahydrocannabinol (THC) in humans. 56 healthy men and women with prior exposure to...

Cannabis smoke and oral Δ9THC enhance working memory in aged but not young adult subjects

bioRxiv (Cold Spring Harbor Laboratory) September 29, 2024 Sabrina Zequeira, Emely A. Gazarov, Alara A. Güvenli et al. preprint

With increased legalization of recreational and medical cannabis, use of this drug is growing rapidly among older adults. As cannabis use can impair cognition in young adults, it is critically important to understand how consumption interacts with the cognitive profile of aged individuals, who are already at increased risk of decline. The current study was designed to determine how cannabis...

Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study

BMC Psychiatry September 27, 2024 Onrumpha Chuenchom, Thanarat Suansanae, Lumsum Lukanapichonchut et al.

Abstract Background Current treatment of cannabis-induced psychosis (CIP) focus on the presenting symptoms of individual patient. Therefore, the objective of this study was to investigate the efficacy of pharmacological treatment for CIP in a retrospective manner. Methods A retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment...

Cannabis and first episode psychosis: Which came first?

Alcoholism & Drug Abuse Weekly September 16, 2024 Alison Knopf

The typical conundrum with cannabis use by adolescents and first episode psychosis — which came first? — was displaced by Steven Batki, M.D. in a plenary session at the Cape Cod Symposium on Addictive Disorders (CCSAD) last week. Bakti, who is professor of psychiatry at the University of California San Francisco Weill Institute for Neurosciences, presented his conclusions allowing the audience...